Status:
ACTIVE_NOT_RECRUITING
Multimodal Sexual Dysfunction Intervention In HCT
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
American Cancer Society, Inc.
The Leukemia and Lymphoma Society
Conditions:
Hematopoietic Stem Cell Transplantation
Hematologic Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This research study is evaluating the impact of an intervention to improve sexual function in stem cell transplant survivors on participants' sexual function, quality of life, and mood. It is expecte...
Detailed Description
Frequently survivors of stem cell transplantation report significant problems with their sexual function that impacts their quality of life, mood, and their intimacy and relationship with their partne...
Eligibility Criteria
Inclusion
- Adult patients (≥ 18 years) with hematologic malignancy who underwent autologous or allogeneic HCT ≥ three months prior to study enrollment.
- Positive screen for sexual dysfunction that is causing distress based on the National Comprehensive Cancer Network (NCCN) survivorship guidelines
- Ability to read and respond to questions in English or to complete questionnaires with assistance from an interpreter.
Exclusion
- Patients with relapsed disease requiring treatment
- Patients with a planned second transplant
- Patients \> 5 years from their HCT
- Patients with psychiatric or cognitive conditions which the treating clinicians believes prohibits compliance with study procedures.
Key Trial Info
Start Date :
February 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT03803696
Start Date
February 1 2019
End Date
December 31 2025
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115